An evolving area of interest is the exploration of therapies that may impact DED in individuals with DM, including diquafosol, topical naltrexone, and sodium/glucose cotransporter 2 (SGLT2) inhibitors [45,46,47]. Here, SLC5A2 is linked to diabetes mellitus.